Temporal association between SARS-CoV-2 and new-onset myasthenia gravis: is it causal or coincidental?

Y Muralidhar Reddy, Santhosh Kumar B, Syed Osman, Jagarlapudi M K Murthy

SUMMARY
Several case reports of COVID-19 in patients with myasthenia gravis (MG) have been documented. However, new-onset autoimmune MG following COVID-19 has been reported very rarely. We report one such case here. A 65-year-old man presented to us with dysphagia 6 weeks following mild COVID-19. He was evaluated and diagnosed as antiacetylcholine receptor antibody (AchR) positive, non-thymomatous, generalised MG. He subsequently developed myasthenic crisis and improved after treatment with intravenous immunoglobulin, prednisolone and pyridostigmine. Systematic literature review showed eight more similar cases. Analysis of all cases including the one reported here showed these features: mean age 55.8 years, male gender (5), time interval between COVID-19 and MG (5–56 days), generalised (5), bulbar and/or ocular symptoms (4), anti-AchR antibodies (7) and antimuscle-specific kinase antibodies (2). All have improved with immunotherapy. Although, many hypothesis are proposed to explain causal relationship between the two, it could as well be sheer coincidence.

BACKGROUND
COVID-19 pandemic is caused by highly infectious SARS-CoV-2. Observational studies have documented several neurological complications or associations either during or after COVID-19. However, direct causality is uncertain. Several case reports and series of COVID-19 in patients with myasthenia gravis (MG) have been documented; in some patients, COVID-19 had worsened the myasthenic weakness resulting in myasthenic crisis and improved after treatment with intravenous immunoglobulin, prednisolone and pyridostigmine. Systematic literature review showed eight more similar cases. Analysis of all cases including the one reported here showed these features: mean age 55.8 years, male gender (5), time interval between COVID-19 and MG (5–56 days), generalised (5), bulbar and/or ocular symptoms (4), anti-AchR antibodies (7) and antimuscle-specific kinase antibodies (2). All have improved with immunotherapy. Although, many hypothesis are proposed to explain causal relationship between the two, it could as well be sheer coincidence.

CASE PRESENTATION
A 65-year-old man, a known patient of diabetes and hypertension, presented to us with dysphagia in the third week of October 2020. He was diagnosed with mild-COVID-19 (nasopharyngeal swab positive for SARS-CoV-2 reverse transcriptase-PCR, RT-PCR) in the first week of September 2020. He was treated with intravenous remdesivir and other supportive therapy. Repeat RT-PCR done in the third week of September was negative. Six weeks after the onset of COVID-19, he developed acute-onset dysphagia for both solids and liquids, which progressed in the subsequent 2 days. He did not report diurnal variation. General examination was unremarkable. Speech showed nasal intonation. Cranial nerve examination showed normal visual acuity, ocular motility, pupillary size and reactivity, mild bifacial weakness, decreased bilateral palatal movements and poor pharyngeal reflex. Motor and sensory examination, deep tendon reflexes, cerebellar and gait examination were normal.

INVESTIGATIONS
MRI of the brain and spinal cord was normal. NCS showed reduced sensory nerve action potential and sensory conduction velocity of ulnar and sural nerves with normal motor nerve conduction parameters suggestive of mild sensory neuropathy. Slow repetitive nerve stimulation (RNS) of nasalis (41%) and trapezius (18.1%) showed a significant decremental response (figure 1). Intravenous neostigmine showed marked improvement in swallowing. Serum antiacetylcholine receptor antibody (AchR) titres were 4.5 nmol/L (<0.40: negative). Serum antimuscle-specific kinase (MuSK) antibody titres were less than 0.18 U/L (<0.40: negative). The SARS-CoV-2 IgG ECLIA antibody titres (Roche diagnostics, USA) were 129 (<1.0: non-reactive). Thyroid function tests were normal. High-resolution CT of the thorax did not reveal thymic hyperplasia or thymoma.

DIFFERENTIAL DIAGNOSIS
We considered the following differential diagnosis in that order of priority after the clinical examination. First, we speculated the possibility of a pharyngocervicobrachial variant of Guillain-Barré syndrome.
## Table 1 Characteristics of 10 cases of post COVID-19 autoimmune myasthenia gravis (MG)

<table>
<thead>
<tr>
<th>Author</th>
<th>Age/gender</th>
<th>Comorbidities and family history</th>
<th>COVID symptoms</th>
<th>COVID Severity</th>
<th>CT chest</th>
<th>COVID-19 treatment</th>
<th>Duration between COVID-19 and MG (in days)</th>
<th>MG type</th>
<th>Thymus pathology</th>
<th>Antibody</th>
<th>SARS-CoV-2 ab lgG titres</th>
<th>MG Treatment</th>
<th>Outcome</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restivo et al</td>
<td>64/M</td>
<td>None</td>
<td>Fever</td>
<td>Mild</td>
<td>Normal</td>
<td>NA</td>
<td>5</td>
<td>Generalised</td>
<td>None</td>
<td>AchR</td>
<td>NA</td>
<td>PSL (75 mg/d); Pyridostigmine (240 mg/d)</td>
<td>Improved</td>
<td>None</td>
</tr>
<tr>
<td>68/M</td>
<td></td>
<td>None</td>
<td>Fever</td>
<td>Mild</td>
<td>Normal</td>
<td>NA</td>
<td>7</td>
<td>Generalised</td>
<td>None</td>
<td>AchR</td>
<td>NA</td>
<td>IVIG (0.4 kg/d x 5 days)</td>
<td>Improved</td>
<td>None</td>
</tr>
<tr>
<td>71/F</td>
<td></td>
<td>None</td>
<td>Cough Fever</td>
<td>Severe</td>
<td>Bilateral Intestinal Pneumonia</td>
<td>5</td>
<td>Generalised</td>
<td>None</td>
<td>AchR</td>
<td>NA</td>
<td>PLEX</td>
<td>Improved</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Sriwastava et al</td>
<td>65/F</td>
<td>Left RCC (S/P nephrectomy); Pituitary adenoma (S/P resection); Pulmonary Carcinoid; Meningioma; Old Pulmonary Embolism</td>
<td>Diarhoea Myalgia</td>
<td>Severe</td>
<td>Bilateral Consolidation</td>
<td>11</td>
<td>Ocular symptoms only</td>
<td>None</td>
<td>AchR</td>
<td>NA</td>
<td>Pyridostigmine (240 mg/d)</td>
<td>Improved</td>
<td>Septic Shock; Dysautonomia (Bradycardia)</td>
<td></td>
</tr>
<tr>
<td>Pérez Álvarez et al</td>
<td>48/M</td>
<td>Schizophrenia; Inverse Psoriasis; Positive ANA</td>
<td>Fever</td>
<td>Mild</td>
<td>Bilateral Consolidation</td>
<td>AZM; HCQS</td>
<td>15</td>
<td>Ocular symptoms only</td>
<td>None</td>
<td>AchR</td>
<td>NA</td>
<td>NA</td>
<td>Improved</td>
<td>None</td>
</tr>
<tr>
<td>Huber et al</td>
<td>21/F</td>
<td>Family history of Hashimotos thyroiditis; Addison's disease; Pernicious anemia</td>
<td>Cold Fatigue Anosmia Ageusia Diarhoea</td>
<td>Mild</td>
<td>Normal</td>
<td>None</td>
<td>15</td>
<td>Ocular symptoms only</td>
<td>None</td>
<td>AchR</td>
<td>Positive</td>
<td>IVIG (0.4 kg/d x 5 days); Pyridostigmine (180 mg/d)</td>
<td>Improved</td>
<td>None</td>
</tr>
<tr>
<td>Assini et al</td>
<td>77/M</td>
<td>None</td>
<td>Fever</td>
<td>NA</td>
<td>Bilateral Intestinal Pneumonia</td>
<td>NA</td>
<td>56</td>
<td>Oculobulbar symptoms only</td>
<td>None</td>
<td>MuSK</td>
<td>NA</td>
<td>Pyridostigmine (240 mg/d); AZT (1.5 mg/kg)</td>
<td>Improved</td>
<td>None</td>
</tr>
<tr>
<td>Muhammed et al</td>
<td>24/F</td>
<td>None</td>
<td>Influenza like syndrome</td>
<td>Mild</td>
<td>NA</td>
<td>None</td>
<td>28</td>
<td>Generalised</td>
<td>None</td>
<td>MuSK</td>
<td>Positive</td>
<td>IVIG PSL; Pyridostigmine</td>
<td>Improved</td>
<td>None</td>
</tr>
<tr>
<td>Our case</td>
<td>65/M</td>
<td>Diabetes Hypertension</td>
<td>Fever, Cold and Cough</td>
<td>Mild</td>
<td>Normal</td>
<td>Remdesivir</td>
<td>42</td>
<td>Generalised</td>
<td>None</td>
<td>AchR</td>
<td>129</td>
<td>IVIG, PSL, AZT Pyridostigmine</td>
<td>Improved</td>
<td>None</td>
</tr>
</tbody>
</table>

AdhR, acetylcholine receptor antibody; ANA, antinuclear antibodies; AZM, Azithromycin; AZT, Azathioprine; f, female; HCQS, Hydroxychloroquine sulfate; IVIG, intravenous immunoglobulin; M, male; MuSK, muscle-specific kinase; NA, not available; PLEX, plasma exchange; PSL, prednisolone; RCC, Renal cell carcinoma.
syndrome (GBS) given the presentation with bulbar symptoms and recent history of COVID-19. Multiple case reports and series of GBS and variants following COVID-19 are published.11 However, the absence of arm and neck weakness at presentation, preserved deep tendon reflexes, absence of demyelination on Nerve conduction studies (NCS) and decremental response on RNS ruled out GBS. Moreover, dramatic clinical response to intravenous neostigmine is also at odds with GBS. Second, botulism was considered. However, the absence of history suggestive of canned or stored food ingestion and further clinical course negated this. Third, central causes like stroke or brain stem demyelination were considered. However, the absence of pyramidal and/or cerebellar signs, preserved sensorium and normal brain imaging ruled out these diseases.

TREATMENT
He was started on oral prednisolone (30 mg/day) and oral pyridostigmine (60 mg every 6 hours). His MG Composite (MGC) score at admission 8. However, there was no improvement, and he needed intravenous neostigmine intermittently. On day 8 of admission, he developed neck and respiratory muscle weakness with a single breath count of eight (MGC 17). Arterial blood gas analysis showed type II respiratory failure (Pco2 52 mm Hg). Because of a myasthenic crisis, he was intubated and connected to a ventilator. Pyridostigmine was stopped, and prednisolone increased to 40 mg/day. He was treated with intravenous immunoglobulin (0.4 mg/kg/day) for five consecutive days. On day 10, he developed upper limb proximal weakness (MGC 33). Tracheostomy was done, anticipating more extended ventilator support on day 14. He showed improvement in neck and limb weakness from day 16 (MGC 31). He was later started on azathioprine (50 mg every 12 hours), pyridostigmine (60 mg every 6 hours) and prednisolone (40 mg every 24 hours) were continued.

OUTCOME AND FOLLOW-UP
With improved respiratory muscle function, he was decannulated on day 21, and an oral soft diet trial was given with a nasogastric tube in situ (MGC 19). He was discharged 2 days later with a nasogastric tube. The patient has been under outpatient follow-up since November 2020 until. His bulbar function improved ultimately in the subsequent 2 weeks and, oral feeds were resumed (MGC 0). Prednisolone (40 mg every 24 hours) was tapered after 2 months of stable course after discharge. He is currently on azathioprine (50 mg every 12 hours) and pyridostigmine (60 mg every 12 hours).

DISCUSSION
Autoimmune MG is a disease of neuromuscular junction caused by autoantibody-mediated destruction of the postsynaptic membrane and characterised clinically by fatigable weakness of skeletal muscles. Various immunosuppressant and immunomodulatory therapies are used in the treatment.12 Few reports showed new onset of MG occurring following varicella zoster, West Nile and Zika virus.13 Thus it is quite possible, MG occurring following COVID-19. To date, there were reports of eight such patients published in the literature.5–10 Clinical features of all nine patients, including one described in this report, are summarised in Table 1. The Majority were aged above 50 years (67%) and suffered mild COVID-19 (75%). The interval between COVID-19 and MG ranged between 5 and 56 days. Five had generalised myasthenia, three had ocular symptoms only and one had ocuolobulbar symptoms only. None had thymic hyperplasia or thymoma. Seven had anti-AChR antibodies, and two had anti-MuSK antibodies. All have improved with immunotherapy. There are many plausible explanations for this causal association. First, antibodies against SARS-CoV-2 might cross-react with AChR and MuSK receptors due to molecular mimicry between the viral proteins and the postsynaptic proteins. The latent period between the COVID-19 and MG favours this hypothesis.1 First, COVID-19 produces a proinflammatory milieu and cytokine storm leading to immune dysregulation and disrupted self-tolerance.1 Third, dormant MG might have been triggered by COVID-19 to become overtly symptomatic.12 Lastly, MG might be triggered by drugs like hydroxychloroquine sulfate and azithromycin prescribed often to treat COVID-19. On the contrary, this association might be sheer coincidental considering the vastly different incidence rates of the two diseases. MG is quite rare, with an annual incidence rate of 2.1–5.0 per 100 000 people.13 In conclusion, MG is a rare post-infectious complication of COVID-19. Longitudinal follow-up of such patients might provide additional insight into this unique link and natural course of the disease.

Acknowledgements Dr. Lalitha P for technical support, Raghu and Kiran ESS for the electrodiagnostics. Contributors YMR has conceptualised the study, compiled the data, conducted the literature search and written the manuscript; SKB and OS have assisted in the management of the case; JMKM has done final revision.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID iD
Y Muralidhar Reddy http://orcid.org/0000-0002-4805-6252

REFERENCES
Case report


Copyright 2021 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions/
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:
► Submit as many cases as you like
► Enjoy fast sympathetic peer review and rapid publication of accepted articles
► Access all the published articles
► Re-use any of the published material for personal use and teaching without further permission

Customer Service
If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.
Visit casereports.bmj.com for more articles like this and to become a Fellow